research 5PSQ-117 Effectiveness of baricitinib in alopecia areata
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
Search
for
Sort by
Research
420-450 / 1000+ resultsresearch Serum levels of ifn-γ, complement component c3 c4 and vitamin d3 in the prognosis of patients with alopecia areata prospective teachers
Alopecia areata patients have higher IFN-γ and low vitamin D3 levels.
research Comparison of Components of Metabolic Syndrome in Androgenic Alopecia versus Healthy Population
People with androgenic alopecia are more likely to have metabolic syndrome than healthy individuals.
research 51223 A novel human disease model of alopecia areata to evaluate benefit of the DHODH inhibitor farudodstat
Farudodstat may effectively treat alopecia areata without harmful side effects.
research Dupilumab for the treatment of alopecia areata in pediatric patients with atopic dermatitis: A scoping review
Dupilumab effectively reduces alopecia areata symptoms in children with atopic dermatitis.
research Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib
Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Quality of Life in Patients with Alopecia Areata presenting to the Department of Dermatology at a Tertiary Care Hospital of Lahore, Pakistan
Alopecia Areata significantly reduces quality of life, especially in women, long-term sufferers, and severe cases.
research Gene Expression Profiles of Melanocytes Over-Expressing miR-5110 in Alpaca
miR-5110 affects alpaca pigmentation by altering specific gene expressions.
research 735 - A case series of dupilumab for vitiligo and alopecia areata in the setting of AD
Dupilumab may help treat hair loss and skin color loss in some patients with atopic dermatitis.
research Genetic Single Nucleotide Polymorphisms of IL-16 and its Concentration of Patients Infected with Alopecia Areata in Diyala Province, Iraq
Certain genetic variations in IL-16 may increase the risk of alopecia areata.
research Different phenotypes in a family with androgen insensitivity caused by the same M780I point mutation in the androgen receptor gene.
The same gene mutation can cause different symptoms in family members.
research 320 An open label clinical trial of Abatacept (CTLA4-Ig) for alopecia areata
Abatacept may help some people with alopecia areata regrow hair.
research Adjunctive Dupilumab Therapy in a Partial Responder to Baricitinib for Alopecia Areata
Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
research Predictive factors for treatment responses to baricitinib in severe alopecia areata: A retrospective, multivariate analysis of 70 cases from a single center
Certain patient traits can predict better hair regrowth with baricitinib in severe alopecia areata.
research 44180 Influence of Baseline Disease Severity Defined by Investigator’s Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study
research Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study
Patients with fewer past treatments for alopecia areata respond better to baricitinib.
research ALLETHRIN INDUCED TOXICOPATHOLOGICAL ALTERATIONS IN ADULT MALE ALBINO RATS
Allethrin caused harmful effects and organ damage in rats, worsening with higher doses and longer exposure.
research Assessment of Vitamin D Level in Patients of Alopecia Areata
Low vitamin D levels are common in people with Alopecia Areata.
research Comparative Study between The Efficacy and Safety of Topical Immune Therapy with Diphenylcyclopropenone versus Anthralin in The Treatment of Resistant Alopecia Areata
Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research AI06 ALUDWIG: an automated artificial intelligence-based assessment of female androgenic alopecia
ALUDWIG can help standardize female hair loss assessment from a single image.
research LB1777 A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
Farudodstat may help treat alopecia areata by protecting hair follicles.
research Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
Dupilumab helps children with alopecia areata regrow hair safely.
research Pigmented contact dermatitis due to therapeutic sensitizer as complication of contact immunotherapy in alopecia areata
Some patients with severe alopecia areata developed skin darkening from their treatment, which may indicate a less effective response to the therapy.
research Association of a polymorphism in the ornithine decarboxylase gene with male androgenetic alopecia
research Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of the Literature
Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.
research Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series
Combining DPCP and anthralin helps regrow hair in some alopecia areata patients.
research BindingDB Entry 50021519: Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment.
research Health‐related quality of life and well‐being in pediatric patients with alopecia areata and their caregivers
Children with alopecia areata and their caregivers experience significant emotional and quality of life challenges.